Soft tissue sarcomas (STS) are rare malignant tumors arising from connective tissues such as muscle, fat, and blood vessels, ...

Intensity Therapeutics (INTS), with a ~$13M market cap, closed up nearly 395% Thursday after publishing phase 1/2 results on ...

Intensity Therapeutics’ stock has risen nearly 400% after its oncology candidate showed high overall survival (OS) and ...

A novel intratumoral treatment was administered to the first patient in a phase 3 trial for certain patients with metastatic soft tissue sarcoma. A phase 3 trial for patients with metastatic soft ...

Ewing sarcoma is one of the most common bone cancers seen in children, and if it spreads, it can be deadly. One study found that under a quarter of children with multi-metastatic Ewing sarcoma ...

Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company ...

Globally, synovial sarcoma remains a rare but aggressive malignancy with a 5-year survival rate of 70% to 80% and a 10-year ...

Shares of Intensity Therapeutics, Inc. (INTS) jumped 188% on Thursday morning after the company announced the publication of ...

Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer Safety and Tolerability of ...

Survival rates from small trial suggest that adding pazopanib to standard treatment for Ewing sarcoma in children may extend lives without adding severe toxicity.